ATXI Logo

Avenue Therapeutics, Inc. (ATXI) 

NASDAQ
Market Cap
$3.98M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
321 of 775
Rank in Industry
191 of 433

Largest Insider Buys in Sector

ATXI Stock Price History Chart

ATXI Stock Performance

About Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Insider Activity of Avenue Therapeutics, Inc.

Over the last 12 months, insiders at Avenue Therapeutics, Inc. have bought $1,250 and sold $86,697 worth of Avenue Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Avenue Therapeutics, Inc. have bought $178,900 and sold $786,189 worth of stock each year.

Highest buying activity among insiders over the last 12 months: KRANZLER JAY D (director) — $1,250.

The last purchase of 497 shares for transaction amount of $1,243 was made by KRANZLER JAY D (director) on 2024‑09‑30.

List of Insider Buy and Sell Transactions, Avenue Therapeutics, Inc.

2024-11-05Saledirector
61
0.0043%
$2.24$137+1.12%
2024-09-30Purchasedirector
497
0.037%
$2.50$1,243-16.47%
2024-09-27Purchasedirector
3
0.0002%
$2.40$7-16.93%
2023-12-11Sale10 percent owner
617,000
4.9094%
$0.14$86,560-59.90%
2023-09-08Purchase10 percent owner
418,410
4.9086%
$0.72$301,255-80.21%
2023-09-08Purchasedirector
348,675
4.0905%
$0.72$251,046-80.21%
2022-10-11Saledirector
388,888
48.3396%
$7.71$3M-59.86%
2021-09-15SaleChief Financial Officer
7,160
0.042%
$1.62$11,599-69.16%
2021-05-06Purchasedirector
2,500
0.0142%
$3.99$9,975-68.56%
2020-08-20SaleChief Financial Officer
3,840
0.0235%
$12.13$46,579-60.88%
2020-03-10PurchaseChief Financial Officer
1,889
0.0115%
$7.94$14,999+12.63%
2020-03-09PurchaseChief Financial Officer
1,500
0.0093%
$7.99$11,983+13.49%
2020-02-27Purchasedirector
2,400
0.0139%
$8.20$19,680+3.72%
2020-02-26Purchasedirector
161
0.001%
$8.73$1,406+0.45%
2020-02-25Purchasedirector
10,000
0.0629%
$9.31$93,100-0.89%
2020-02-25PurchaseChief Financial Officer
1,200
0.0074%
$9.09$10,908-0.89%
2019-09-12Purchasedirector
16,000
0.0982%
$6.27$100,320+46.39%
2019-08-09SaleChief Financial Officer
2,375
0.0138%
$5.56$13,205+49.32%
2019-08-08SaleChief Financial Officer
2,313
0.0141%
$5.62$12,999+55.35%
2019-06-18Purchasedirector
2,000
0.0126%
$5.83$11,660+21.09%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.